(vii) Among patients with DM, CADM, or CDM, anti-MDA5 antibody-positive patients consistently had higher ILD and RP-ILD rates, LDH levels, lower lymphocyte levels, and worse prognoses than those who were negative for anti-MDA5 antibodies. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.